1y return+150.7%S&P 500 +20.9%
3y return+169.1%S&P 500 +68.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2022: $305 against $195 in the S&P 500.2
Saturn V Capital Management LPS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| AMLXAmylyx Pharmaceuticals Inc | $83.0M | 11.9% | +6.3% |
| ALMSAlumis Inc | $82.0M | 11.8% | −9.0% |
| ABVXAbivax Sa | $69.1M | 9.9% | −4.4% |
| PCVXVaxcyte Inc | $49.6M | 7.1% | +3.4% |
| IMMXImmix Biopharma Inc | $48.0M | 6.9% | +26.1% |
| Pharvaris N VCUSIP N69605108 | $45.4M | 6.5% | +9.4% |
| Jazz Pharmaceuticals PLCCUSIP G50871105 | $38.8M | 5.6% | −1.2% |
| CELCCelcuity Inc | $38.7M | 5.6% | +31.4% |
| IRONDisc Medicine Inc | $38.4M | 5.5% | +16.6% |
| CADLCandel Therapeutics Inc | $34.0M | 4.9% | +14.1% |
| XFORX4 Pharmaceuticals Inc | $32.6M | 4.7% | +8.0% |
| MNPRMonopar Therapeutics Inc | $28.9M | 4.1% | −9.7% |
| DYNDyne Therapeutics Inc | $23.5M | 3.4% | +9.4% |
| TRVITrevi Therapeutics Inc | $19.6M | 2.8% | New |
| Zura Bio LtdCUSIP G9TY5A101 | $12.4M | 1.8% | +184.0% |
| SGMTSagimet Biosciences Inc | $11.4M | 1.6% | New |
| Oculis Holding AgCUSIP H5870P102 | $9.5M | 1.4% | +32.5% |
| IKTInhibikase Therapeutics Inc | $7.9M | 1.1% | |
| VIRVir Biotechnology Inc | $7.9M | 1.1% | New |
| IVVDInvivyd Inc | $7.3M | 1.0% | −23.4% |
| ANROAlto Neuroscience Inc | $4.8M | 0.7% | +105.4% |
| MSLESatellos Bioscience Inc | $2.7M | 0.4% | |
| OVIDOvid Therapeutics Inc | $1.8M | 0.3% | −84.1% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| AMLXAmylyx Pharmaceuticals Inc | December 31, 2024 | +375.1% | $83.0M |
| ALMSAlumis Inc | December 31, 2025 | +188.3% | $82.0M |
| DYNDyne Therapeutics Inc | June 30, 2025 | +133.3% | $23.5M |
| Jazz Pharmaceuticals PLCCUSIP G50871105 | June 30, 2025 | +127.1% | $38.8M |
| CADLCandel Therapeutics Inc | March 31, 2026 | +110.2% | $34.0M |
| IMMXImmix Biopharma Inc | December 31, 2025 | +97.1% | $48.0M |
| OVIDOvid Therapeutics Inc | December 31, 2025 | +65.0% | $1.8M |
| Pharvaris N VCUSIP N69605108 | September 30, 2025 | +38.6% | $45.4M |
| MSLESatellos Bioscience Inc | March 31, 2026 | +38.1% | $2.7M |
| IRONDisc Medicine Inc | December 31, 2023 | +26.6% | $38.4M |
Sold off last quarter
- COGTCogent Biosciences Inc was $24.1M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +18.2% | +14.8% |
| March 31, 2026 | +9.1% | −4.6% |
| December 31, 2025 | +29.7% | +2.4% |
| September 30, 2025 | +50.0% | +7.8% |
| June 30, 2025 | +10.1% | +10.5% |
| March 31, 2025 | −16.6% | −4.6% |
| December 31, 2024 | −15.8% | +2.1% |
| September 30, 2024 | +9.7% | +5.4% |
| June 30, 2024 | −2.6% | +4.0% |
| March 31, 2024 | +9.9% | +10.0% |
| December 31, 2023 | +19.4% | +11.2% |
| September 30, 2023 | −1.0% | −3.6% |
| June 30, 2023 | +13.6% | +8.3% |
| March 31, 2023 | −0.1% | +7.0% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Saturn V Capital Management LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1964437&type=13F-HR&dateb=&owner=include&count=40CIK 1964437
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1964437/000196443726000012/Filed August 14, 2026 · accession 0001964437-26-000012